Profil
María Eugenia Zarabozo is associated with two companies, Aptus Biotech SL and AptaTargets SL.
She is the founder of both companies.
At Aptus Biotech SL, she held the position of Chief Financial & Legal Officer.
At AptaTargets SL, she holds the position of Chief Financial Officer & Director.
Postes actifs de María Eugenia Zarabozo
Sociétés | Poste | Début |
---|---|---|
AptaTargets SL
AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Fondateur | 01/01/2014 |
Anciens postes connus de María Eugenia Zarabozo
Sociétés | Poste | Fin |
---|---|---|
Aptus Biotech SL
Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Aptus Biotech SL
Aptus Biotech SL BiotechnologyHealth Technology Aptus Biotech SL develops drug candidates using its aptamer platform. It is a biotechnology company specializing in the development and customization of Aptamers fully adapted to the needs of each application. The firm’s product Aptateca, offers a catalog of aptamers. The company was founded by David Segarra and María Eugenia Zarabozo in 2010 and is headquartered in Madrid, Spain. | Health Technology |
AptaTargets SL
AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |